Клинико-экономическая оценка применения квинаприла
- Р Р‡.МессенРТвЂВВВВВВВжер
- РћРТвЂВВВВВВВнокласснРСвЂВВВВВВВРєРСвЂВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВровать ссылку
Full Text:
Abstract
Conflicts of Interest Disclosure:
The authors declares that there is no conflict of interest.
Article info:
Date submitted: 26.06.2018
Published: 26.06.2018
All authors have read and approved the final manuscript.
Peer review info:
"Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice" thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Editorial comment:
In case of any discrepancies in a text or the differences in its layout between the pdf-version of an article and its html-version the priority is given to the pdf-version.
About the Authors
Ю. БелоусовRussian Federation
В. Григорьев
Russian Federation
References
1. Acanfora D., Furgi G., Trojano L. et al. Quinapril in patients with congestive heart failure: controlled trial versus captopril // Am J Ther. - 1997. - 4(5-6):181-188
2. Anderson T.J., Elstein E., Haber H., Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF Study) // J.Am.Coll-Cardiol.. - 2000. - 35:60-66
3. Barthelemy C., Eurin J., Lechat P. et al. The mechanism of the angiotensin-converting enzyme inhibitor quinapril is not related to bradykinin level in heart tissue // Peptides. - 2002. - Vol.23. - No.6.:1161-1169
4. Borch4Johnsen K. The cost of nephropathy in Type 2 diabetes // Pharmacoeconomics. - 1995. (Suppl. 1). - P.40-45.
5. Brenner B.M., Cooper M.E., Zeeuw D.D. et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) // J.Renin. Angiotensin. Aldosterone. Syst. - 2000. - Vol.1. - No-4.:328-335.
6. Cashin4Hemphill L., Holmvang G. Et al. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. Am J Cardiol 1999;83:43447
7. Chobanian A.V, Bakris G.L., Black H.R. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572
8. Conroy et al, Eur Heart J, 2003, 24:987-1003
9. Dalal P.M., Parab P.V. Cerebrovascular disease in type 2 diabetes mellitus // Neurol India. 2002 Dec;50(4):380-385
10. De Vegt F., Dekker J.M., Ruhe H.G. et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study // Diabetologia. - 1999. - Vol-42. - P.926-931
11. Diet F., Pratt R.E., Berry G.J. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996-94:2756-67
12. Dominguez L.J., Barbagallo M., Kattah W. et al. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects // Am. J. Hypert. - 1995. - Vol.8. - P.808-814
13. Dzau V., Bernstein K., Celermaier D. et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88 (Suppl L):1-20
14. Eastman R.C., Cowie C.C., Harris M.I. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk // Diabetes Care. - 1997. - Vol.20. - P.127-128.
15. Elliott W.J. The economic impact of hypertension // J Clin Hypertens (Greenwich). 2003 May-Jun;5(3 Suppl 2):3-13.
16. Gall M.A., Rossing P., Skott P. et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulindependent) diabetic patients // Diabetologia. - 1991. - Vol.34. - P.655-661.
17. Goldberg R.B. Cardiovascular disease in diabetic patients // Med. Clin. North Am. -2000. - Vol.84. - N1. - P.81-93.
18. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053
19. Horning B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997-95:1115-8
20. http://hd13.narod.ru/books/much01/muh01-1-4.htm
23. Kramer H.J., Nguyen Q.D., Curhan G., Hsu C.Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus // JAMA. 2003 Jun 25;289(24):3273-3277.
24. Kurth T., Gaziano J.M., Berger K. et al. Body mass index and the risk of stroke in men // Arch Intern Med. 2002 Dec 9.23;162(22):2557-62.
25. Lausanne J.B. Stroke prevention by the practitioner // Cerebrovasc Dis. 2003;15 Suppl 2:1-69
26. Lonn E.M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69
27. Mancini G.B.J., Henry G.C., Macaya C. et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study Circulation 1996;94:258-65
28. Martin S., Reipen M., van Leendert R., Beuth J., Kolb H., Scherbaum W.A. Pilot study of controlled retrospective analysis (retrolective study design) of care for type 2 diabetics since 1990 // Dtsch Med Wochenschr. 2003 May 23;128(21):1173-1178.
29. Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77
30. Pitt B., O’Neill B., Feldman R. et al. QUIET Study Group. The Quinapril Ischemic Event Trial (QUIET) evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63
31. Ravid M., Lang R., Rachmani R., Lister M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus // Arch-Int-Med. - 1996. - Vol.156. - P.286-289
32. Ritz E. Nephropathy in type 2 diabetes // J. Intern-Med. - 1999. - Vol.245. - No 2. - P.111-126.
33. Simpson D., Noble S., Goa K.L. Perindopril: in congestive heart failure // Drugs. 2002;62(9):1367-1377
34. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991-325:293-302
35. Watts G.F. Diabetic renal disease // In: Diabetic complications / Ed. Shaw K.M. - Wiley, 1996. - P.27-52.
36. Wrenger E., Neumann K.H., Lehnert H. Diagnostics and therapy of diabetic nephrology // Urologe A. 2003 Feb;42(2):W269-84
37. www.athero.ru
38. www.escardio.org
39. Yamada H., Fabris B., Allen AM. et al. Localization of angiotensin-converting enzyme in rat heart. Circ Res 1991;68:141-9, Falkenhahn M, Franke F, Bohle RM, et al. Cellular distribution of angiotensin-converting enzyme after myocardial infarction- Hypertension 1995;25:219-26
40. Almazov V.A., Blagosklonnaya Ya.V., Shlyakhto E.V., Krasil'nikova E.I. Sindrom insulinorezistentnosti (istoriya voprosa, patogenez, podkhody k lecheniyu)) // 100 let kafedre fakul'tetskoi terapii im.akad. G.F.Langa. Vazhneishie dostizheniya i vernost' traditsiyam: Sbornik nauchnykh trudov. - SPb.: Izd. SPb GMU, 2000. - S. 353-363
41. Belousov Yu.B., Karpov O.I., Kobalava Zh.D., Kotovskaya Yu.V. Kliniko-ekonomicheskie aspekty profilaktiki mozgovogo krovoobrashcheniya po dannym issledovaniya ELSA // Kachestvennaya klinicheskaya praktika. - 2002. - №3. - S. 76-88
42. Gadzhiev A.N. Ingibitor AFP kvinapril v lechenii khronicheskoi serdechnoi nedostatochnosti // Ter.arkhiv. - 2003. - 75(1):51-55; Culy C.R. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders // Drugs - 2002; 62(2): 339-85
43. Dedov I.I., Aleksandrov A.A. Problemy i perspektivy gipolipidemicheskoi terapii pri sakharnom diabete (soobshchenie 1) // Sakharnyi diabet. - 2000. - №2. - S. 9-12.
44. Dedov I.I., Shestakova M.V. Diabeticheskaya nefropatiya. - M.: Universum Pablishing, 2000. - 237 s.
45. Zalevskaya A.G. Mikrososudistye oslozhneniya sakharnogo diabeta: sovremennyi vzglyad na lechenie // Sankt-Peterburgskie vrachebnye vedomosti. - 1997. - № 17. - S.80-82.
46. Karpov Yu.A. Klinicheskie posledstviya ingibirovaniya tkanevogo angiotenzinprevrashchayushchego fermenta: tselesoobraznost' pri stabil'noi IBS. Kardiologiya 2002; 6:117-22.
47. Sokolov E.I. Sakharnyi diabet i ateroskleroz. - M.: Nauka, 1996. - 404 s.
48. Shestakova M.V. Diabeticheskaya nefropatiya: itogi KhKh veka, perspektivy XXI veka // Sakharnyi diabet. - 2000. - №1. - S. 15-18.
49. Falkenhahn M, Franke F, Bohle RM, et al. Cellular distribution of angiotensin.converting enzyme after myocardial infarction. Hypertension 1995;25:219-26
50. Culy C.R. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders // Drugs - 2002; 62(2): 339-85
51. Belenkov Yu.N., Chazova I.E., Mychka V.B. Mnogotsentrovoe randomizirovannoe otkrytoe issledovanie po izucheniyu effektivnosti izmeneniya obraza zhizni i terapii ingibitorami APF (kvinaprilom) u bol'nykh ozhireniem i arterial'noi gipertoniei (EKO)// Arterial'naya gipertenziya, tom 9, №6, 2003
52. Flack J.M., Yunis C. et al. The Rapidity of Drug Dose Escalation Influences Blood Pressure Response and Adverse Effects Burden in Patients With Hypertension The Quinapril Titrtion Interval Management Evaluation (ATIME) Study.//Arch Intern Med Vol 160, June 26, 2000; 1842-46
53. Belenkov Yu.N., Mareev V.Yu., Ageev F.T. Ingibitory angiotenzin-prevrashchayushchego fermenta v lechenii serdechno-sosudistykh zabolevanii (Kvinapril i endotelial'naya disfunktsiya). - M., 2002
Review
For citations:
, . Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2004;(1):46-56. (In Russ.)
ISSN 2618-8473 (Online)